Inmunoterapia en 1L del CPCNP: monoterapia y/o tratamiento combinado - page 29

Durvalumab plus Tremelimumab

Antonia S, et al. Lancet Oncol 2016

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,19,20,21,22,23,24,25,26,27,28 30,31,32,33,34,35,36,37,38,39,...42